Featured Company News – TapImmune Announced Final Patient Enrollment Ahead of Schedule in Phase-2 Cancer Vaccine Study For TNBC

Research Desk Line-up: Repligen Post Earnings Coverage

LONDON, UK / ACCESSWIRE / November 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for TapImmune, Inc. (NASDAQ: TPIV), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=TPIV. The Company announced on November 14, 2017, the enrollment of the final patient in a randomized Phase-2 clinical study of its novel T-cell vaccine candidate TPIV200 for treating triple-negative breast cancer (TNBC). For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Repligen Corporation (NASDAQ: RGEN) for due-diligence and potential coverage as the Company reported on November 09, 2017, its financial results for Q3 2017 which ended on September 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Repligen when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on TPIV; also brushing on RGEN. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=TPIV

http://protraderdaily.com/optin/?symbol=RGEN

TapImmune Evaluating TPIV200 in Multiple Ongoing Phase-2 Trials

The Company, along with its clinical partners, is evaluating TPIV200 in multiple ongoing Phase-2 trials for treating ovarian and breast cancers, and is currently enrolling patients. For this, Mayo Clinic is sponsoring a 280-patient efficacy trial to evaluate disease-free survival in women with advanced TNBC. This study is fully funded by a $13.3 million grant from the US Department of Defense. Patient dosing is likely to begin by the end of 2017.

Vaccination with TPIV200 May Potentially Delay or Prevent Cancer Recurrence

Dr. Richard Kenney, Head of Clinical Development for TapImmune, stated that the Company is pleased to complete enrollment in this study almost two months ahead of its original projections. The Company’s Phase-2 trial focuses on women who have completed initial surgery and radiation/chemotherapy for TNBC at least 60 days prior to randomization. Vaccination with TPIV200 during this important window may potentially delay or prevent cancer recurrence by generating robust T-cell immunity against tumor cells. Richard added that evaluating multiple vaccine dosing strategies in this Phase-2 trial may enhance the ability to generate optimal immune responses.

TapImmune to Report Interim Immunogenicity Results in First Half of 2018

Peter Hoang, President and CEO of TapImmune, mentioned that TNBC is a difficult-to-treat condition, but one where patients may stand to benefit significantly from immunotherapies that are effective at continually fighting off disease progression long after initial cancer therapy. As a multi-peptide therapeutic vaccine, TPIV200 is designed to do just that. Peter added that the Company looks forward to reporting interim immunogenicity results in the first half of 2018 and continuing the booster phase of this Phase-2 dosing study as well as to Mayo Clinic initiating the long-term Phase-2 efficacy study in TNBC.

Phase-2 Clinical Trial

The randomized, multi-center study is designed to help determine the optimal vaccine dose and regimen to maximize the immune response generated against the vaccine’s molecular target, folate receptor-alpha (FRa), highly correlated with cancer recurrence. The study enrolled more than 80 women, who have completed initial surgery and radiation/chemotherapy, and who have not yet had a cancer recurrence. The study randomized patients to receive six monthly injections with different doses of TPIV 200. Patients will continue to receive booster vaccine every six months while they remain progression-free. The primary endpoint of the Phase-2 study is the immune response against the vaccine target, FRa, as measured by the presence of anti-FRa T cells.

What is Triple-Negative Breast Cancer?

TNBC refers to any breast cancer that does not express the three most common types of receptors known to fuel most breast cancer growth, estrogen, progesterone, and the HER-2/neu gene. This makes it more difficult to treat since most hormone therapies target one of the three receptors, so triple-negative cancers often require combination therapies.

About TPIV200

TPIV200 is a novel peptide-based cancer vaccine that has been shown to induce a robust and long-lasting memory T-cell immune responses directed against Fra, a molecule that is overexpressed on the surface of the vast majority of TNBC cancer cells and is associated with cancer recurrence. TPIV 200 has been granted both Orphan Drug and FDA Fast Track Designation for treating ovarian cancer.

About TapImmune, Inc.

Established in 1992, TapImmune, Inc. is a leading clinical-stage immuno-oncology company developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. The Company is advancing two clinical stage T-cell vaccine candidates in multiple Phase-II and Phase-Ib/IIa clinical trials for treating ovarian and breast cancers. TapImmune is headquartered in Jacksonville, Florida.

Last Close Stock Review

At the close of trading session on Wednesday, November 15, 2017, TapImmune’s stock price advanced 1.45% to end the day at $2.66. A total volume of 9.81 thousand shares were exchanged during the session. At Wednesday’s closing price, the stock’s net capitalization stands at $26.98 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 482163